CRNX Stock Forecast & Price Target

Crinetics Pharmaceuticals Inc has demonstrated a promising financial outlook, particularly with its flagship product, Palsonify, as revenue estimates for 2026 have been increased to $62 million from a previous $49 million, reflecting strong sales performance. In the fourth quarter of 2025, the company reported over $5 million in net product revenue for Palsonify, significantly surpassing both consensus estimates and prior forecasts, indicating robust market acceptance and potential for future revenue growth. Furthermore, with early adoption rates showcasing approximately 30% of endocrinologists prescribing Palsonify, alongside a positive early patient experience, Crinetics appears well-positioned for sustained growth and expansion in the global acromegaly market.

Crinetics Pharmaceuticals is facing significant commercial and financial headwinds that contribute to a negative outlook on its stock. The anticipated sales potential of its main product, Palsonify, is threatened by concerns over liver enzyme elevations, competition, and challenges in differentiating its offerings from existing treatments, resulting in a reduction of peak sales estimates in the EU. Furthermore, the company is expected to continue incurring net losses throughout the commercialization phase and into the early launch period, compounded by regulatory and clinical trial risks that could further impact its financial stability and growth prospects.